Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 792 Shares

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 792 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $146.04, for a total transaction of $115,663.68. Following the completion of the sale, the chief financial officer now owns 71,869 shares of the company's stock, valued at approximately $10,495,748.76. This trade represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The shares were sold at an average price of $176.88, for a total transaction of $7,694,633.76.
• On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $719,046.45.
• On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total transaction of $333,067.60.
• On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total transaction of $233,416.54.
• On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The stock was sold at an average price of $171.98, for a total transaction of $162,693.08.
• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.

Natera Stock Performance

NTRA traded up $1.52 on Friday, reaching $151.15. The stock had a trading volume of 3,420,538 shares, compared to its average volume of 1,339,250. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The business's 50-day moving average price is $161.23 and its two-hundred day moving average price is $150.01. The company has a market cap of $20.43 billion, a P/E ratio of -85.88 and a beta of 1.80.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million during the quarter, compared to analysts' expectations of $447.91 million. Sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Institutional Trading of Natera

Institutional investors have recently modified their holdings of the stock. Cerity Partners LLC grew its position in shares of Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company's stock valued at $10,936,000 after purchasing an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in shares of Natera in the third quarter valued at about $385,000. Everence Capital Management Inc. acquired a new stake in shares of Natera in the fourth quarter valued at about $573,000. Alpha DNA Investment Management LLC acquired a new stake in shares of Natera in the third quarter valued at about $505,000. Finally, First Turn Management LLC acquired a new stake in shares of Natera in the third quarter valued at about $19,760,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Piper Sandler lifted their price objective on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. Canaccord Genuity Group reiterated a "buy" rating and set a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. Morgan Stanley lifted their price objective on shares of Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. BTIG Research reiterated a "buy" rating on shares of Natera in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, December 13th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.